Drug intelligence / Profile preview

Biokine Cardio

Development stage: Unknown
Lead developer: Adamas Biotech
Modality: Small Molecules
Administration: Oral

Overview

Biokine Cardio is a nutraceutical candidate developed by Adamas Biotech, currently in Phase 1 clinical development for the treatment of diabetic cardiomyopathy. The product is based on green tea catechins, which are believed to provide therapeutic benefits through antioxidant activity and metabolic support, potentially protecting the heart from damage caused by chronic hyperglycemia and oxidative stress associated with diabetes.

Brand names: Biokine Cardio
Other names: Biokine (Cardio)

Beyond the preview

Go deeper on Biokine Cardio.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Biokine Cardio.

Explore the full profile